z-logo
Premium
Malignancies after renal transplantation in southern Taiwan: experience in one centre
Author(s) -
Feng WenWei,
Wang TsuNai,
Chen HsiuChao,
Ho JiChen,
Ko YingChin
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06645.x
Subject(s) - medicine , cumulative incidence , incidence (geometry) , transplantation , skin cancer , cancer registry , cancer , standardized mortality ratio , kidney transplantation , cohort , population , bladder cancer , kidney cancer , oncology , physics , environmental health , optics
OBJECTIVE To present data on cancer distribution in renal‐transplant recipients in Chinese people, as in Western studies renal‐transplant recipients are reportedly at greater risk of malignancies, especially skin cancer, but there is limited information in Chinese people. PATIENTS AND METHODS Using the data of a cancer registry, we compared a hospital‐based cohort of 283 renal‐transplant recipients between 1981 and 2002 with the general population in Taiwan, to identify the incidence and risk factors of cancer. RESULTS The cumulative period of observation was 22 582.93 person‐months. Twenty‐five patients (8.83%) developed malignancies after renal transplantation; the standardized incidence ratio was 4.6 (95% confidence interval 2.84–6.48). Bladder and renal cancers were commonest, and the cumulative incidence rate (CIR) was 4.59%. The second most frequent type was hepatoma, where the CIR was 1.77%. The third was malignant tumour of the skin, with a CIR of 1.41%; these comprised three Kaposi’s sarcoma and one malignant lymphoma, with no incidence of squamous or basocellular skin cancer. CONCLUSION Compared with Western countries, the distribution pattern of cancer after kidney transplantation was different, with no squamous or basocellular skin cancers, and a very high incidence of kidney and urinary tract cancer.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here